CytoDyn Inc. has announced upcoming presentations of new clinical data on leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor, at the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity, scheduled for September 24-27, 2025, in Montreal, Canada. The company will deliver both oral and poster presentations detailing leronlimab's effects on PD-L1 expression and patient survival in metastatic triple-negative breast cancer (mTNBC). According to CytoDyn, key findings include increased PD-L1 expression in circulating tumor cells following leronlimab treatment, a correlation between CCR5 expression and T cell infiltration, and improved overall survival rates when CCR5 inhibition is combined with immune checkpoint inhibitor therapy. These results will be presented during the conference, with the poster session set for September 26 and the oral presentation on September 27.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534888-en) on September 25, 2025, and is solely responsible for the information contained therein.
Comments